HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

APT198K

combination of xyloglucan, plus heat-killed Lactobacillus reuteri, plus Bifidobacterium brevis for treatment of infantile colic

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Macromolecular Substances: 97
- Polymers: 13051
  - Biopolymers: 773
    - Glucans: 1624
      - APT198K: 1
Carbohydrates: 22023
- Polysaccharides: 15383
  - Glucans: 1624
    - APT198K: 1
  - Xylans: 58
    - APT198K: 1

Experts

1.	Bacarea, Anca: 1 article (03/2017)
2.	Bacarea, Vlad: 1 article (03/2017)
3.	Constantin, Mariana: 1 article (03/2017)
4.	Manolache, Mihai: 1 article (03/2017)
5.	Marusteri, Marius: 1 article (03/2017)
6.	Vandenplas, Yvan: 1 article (03/2017)

Related Diseases

1.

Colic (Abdominal Cramps)

03/01/2017 - "Efficacy and safety of APT198K for the treatment of infantile colic: a pilot study."
03/01/2017 - "Randomized, multicenter, open-label, parallel group, active-controlled study, in 46 infants aged 3-16 weeks with infantile colic, receiving APT198K or a lactase dietary supplement for 10 days. "
03/01/2017 - "APT198K decreased the mean duration per crying episode significantly more than a lactase dietary supplement in infants with colic. "
03/01/2017 - "Comparing efficacy and safety of APT198K (xyloglucan plus heat-killed Lactobacillus reuteri SGL01 and Bifidobacterium brevis SGB01) versus a lactase dietary supplement as first-line treatment of infantile colic. "

Related Drugs and Biologics

1.	Lactase
2.	xyloglucan